For research use only
| Cat No. | ABC-X0043C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
ETV6-BTK (C481G) BAF3 Cell Line is designed for investigating BTK inhibitor resistance and targeted therapeutic screening in leukemia models.
The ETV6 BTK (C481G) BAF3 Cell Line stably expresses the ETV6-BTK fusion protein carrying the C481G mutation, introduced via lentiviral transduction. This mutation affects BTK’s covalent inhibitor binding site, conferring resistance to ibrutinib. Edited clones are validated at the molecular level.
Target
ETV6-BTK fusions promote BTK-dependent survival signaling. The C481G mutation is associated with drug resistance in B-cell malignancies, impairing irreversible inhibitor efficacy. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0043C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Ideal for studying BTK-driven lymphoid malignancies and for evaluating next-generation non-covalent BTK inhibitors.